更新于：2024-06-30
Eldecalcitol
艾地骨化醇
更新于：2024-06-30
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C30H50O5 |
InChIKeyFZEXGDDBXLBRTD-AYIMTCTASA-N |
CAS号104121-92-8 |
关联
59
项与 艾地骨化醇 相关的临床试验Efficacy and Safety of Eldecalcitol in Preventing Glucocorticoid-induced Bone Loss in Rheumatoid Arthritis Patients (ELEGANT)
评估受试制剂艾地骨化醇软胶囊（规格：0.75 μg）与参比制剂艾地骨化醇软胶囊（商品名：艾地罗®，规格：0.75 μg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究
中国健康受试者空腹及餐后口服艾地骨化醇软胶囊（0.75μg）单中心、开放、随机、单剂量、两周期、两序列自身交叉生物等效性试验
100 项与 艾地骨化醇 相关的临床结果
登录后查看更多信息
100 项与 艾地骨化醇 相关的转化医学
登录后查看更多信息
100 项与 艾地骨化醇 相关的专利（医药）
登录后查看更多信息
259
项与 艾地骨化醇 相关的文献（医药）2024-01-01Medical principles and practice : international journal of the Kuwait University, Health Science Centre
Factors Affecting the Second Complete Atypical Femoral Fracture after the First Atypical Fracture
Article
作者: Tsuchie, Hiroyuki ; Saito, Hikaru ; Tomite, Takenori ; Shibata, Nobusuke ; Kinoshita, Hayato ; Takeshima, Masaaki ; Nozaka, Koji ; Miyakoshi, Naohisa ; Inoue, Jyunichi ; Akagawa, Manabu ; Abe, Hidekazu ; Miura, Takanori ; Maekawa, Shigeto ; Aizawa, Toshiaki ; Yuasa, Yusuke ; Ouchi, Kentaro ; Sasaki, Ken ; Mita, Motoki ; Fujii, Masashi ; Kasukawa, Yuji
Objectives: Atypical femoral fracture (AFF) is an atypical low-energy subtrochanteric and diaphyseal femoral fracture. Even if bone fusion is achieved in patients with AFF, the risk of AFF in the contralateral femur must be considered. This study aimed to investigate the factors affecting complete AFF in the contralateral femur and conservatively treated incomplete AFF. Subject and Methods: Radiographs of 111 femurs in 104 AFF cases were examined, and the femurs were classified as follows: 85 contralateral femurs with complete AFF; 18 contralateral femurs with incomplete AFF; 8 femurs with incomplete AFF without surgical treatment. Various patients’ clinical data were collected, and we investigated the factors affecting the second complete AFF. Results: Complete fractures occurred in 10 (9.7%) of 103 femurs without incomplete AFF at the first visit and in 3 (37.5%) of 8 femurs with incomplete AFF. The Kaplan-Meier curve revealed that lateral cortical bone thickening and thigh pain were associated with significantly poorer prognoses (p = 0.026 and p = 0.013, respectively). Multivariate analyses revealed that eldecalcitol usage after AFF onset (p = 0.0094) and previous use of bisphosphonate or denosumab (p = 0.0126) were protective factors for second complete AFF and that the presence of thigh pain (p = 0.0134) was a risk factor for second complete AFF. Conclusions: Eldecalcitol administration after bone union of first AFF may prevent AFF recurrence. In addition, painful incomplete AFF has a high risk of developing a complete fracture.
2024-04-01European journal of pharmacology
ED-71 ameliorates bone regeneration in type 2 diabetes by reducing ferroptosis in osteoblasts via the HIF1α pathway
Article
作者: Zhang, Zhanwei ; Li, Binyang ; Ma, Gaoqiang ; Zhang, Dongjiao ; Liu, Yingxue ; Wang, Maoshan ; Yu, Gyeonghwi ; Gui, Houda ; Wu, Ailin ; Xu, Xin
Eldecalcitol (ED-71), a novel active form of vitamin D, shows potential in treating osteoporosis. However, its underlying mechanisms of action remain to be determined. This study aimed to investigate the effect of ED-71 on bone regeneration and to illustrate its mode of action. The in-vitro model was developed using rat primary osteoblasts cultured under high-glucose conditions, and these cells were treated with ED-71. Additionally, an in vivo model of cranial bone defects was established in type 2 diabetic rats, and ED-71 was administered by gavage. The results demonstrated that ED-71 prevented osteoblast cell death, enhanced rat primary osteoblasts' osteogenic capacity, and attenuated the overexpression of hypoxia-inducible factor 1α (HIF1α) induced by high glucose levels. Furthermore, ED-71 increased glutathione peroxidase 4 (GPX4) levels and inhibited ferroptosis in response to hyperglycemic stimulation. Notably, interference with the HIF1α activator and ferroptosis activator Erastin significantly reduced the therapeutic effects of edetate osteolysis. These findings were further tested in vivo experiments. These results suggest that ED-71 activates the HIF1α pathway in vivo and in vitro, effectively relieving the ferroptosis induced by high glucose. Significantly, ED-71 may improve osteogenic disorders caused by diabetes.
2023-11-01Journal of bone and mineral metabolism
Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis
Article
作者: Fukasawa, Toshiki ; Yoshida, Satomi ; Ri, Kairi ; Masuda, Soichiro ; Kawakami, Koji ; Takeuchi, Masato ; Tanaka, Shiro
INTRODUCTION:
Eldecalcitol (ELD) is an active vitamin D3 analog (AVD) commonly used to treat osteoporosis in Japan. Although routine monitoring of serum calcium levels during ELD therapy is recommended, little is known about the actual frequency and determinants of monitoring.
MATERIALS AND METHODS:
This was a descriptive cohort study using a Japanese electronic medical records database. We identified osteoporosis patients who initiated treatment with ELD or other AVDs (alfacalcidol and calcitriol) between April 1, 2011 and September 10, 2021. The index date for cohort entry was the first prescription date of ELD or other AVDs. The frequency of serum calcium monitoring was evaluated every 6 months. Determinants of serum calcium monitoring were identified using multivariable logistic regression models. We also calculated the incidence of hypercalcemia and the frequency of serum calcium monitoring within 6 months before hypercalcemia.
RESULTS:
We identified 12,671 ELD users and 7867 other AVD users. Within 6 months after cohort entry, 45.9% of ELD users and 58.7% of other AVD users underwent serum calcium monitoring. Female sex, no use of systemic corticosteroids, moderate-to-good renal function, treatment in smaller hospitals, and treatment in orthopedic surgery departments were associated with a lower likelihood of receiving serum calcium monitoring during ELD therapy. The incidence of hypercalcemia among ELD users was 6.36 per 100 person-years, with 20.6% of cases not receiving serum calcium monitoring before hypercalcemia.
CONCLUSION:
Our findings suggest that serum calcium monitoring is not given adequate attention during ELD therapy in routine clinical practice.
100 项与 艾地骨化醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 日本 | 2011-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性骨质疏松症 | 临床3期 | 中国 | 2015-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 鏇鑰選壓遞願醖獵醖顧(鬱網膚夢願淵構顧壓觸) = 窪窪糧顧選構廠壓範顧 願鏇積鏇顧廠鏇選餘艱 (艱選積製壓壓鏇顧繭蓋 ) | 积极 | 2014-05-01 | ||
鏇鑰選壓遞願醖獵醖顧(鬱網膚夢願淵構顧壓觸) = 築鹽鬱觸築餘膚鹹艱淵 願鏇積鏇顧廠鏇選餘艱 (艱選積製壓壓鏇顧繭蓋 ) | |||||||
临床3期 | 1,054 | 艱淵簾築餘構選獵製窪(齋範憲鹽遞鬱築鏇憲構) = 憲憲築廠顧鏇憲齋壓壓 鬱衊衊築顧壓鹹窪簾網 (繭願選網範簾獵膚憲衊, 0.56 ~ 0.97) | 积极 | 2011-10-01 | |||
艱淵簾築餘構選獵製窪(齋範憲鹽遞鬱築鏇憲構) = 淵遞糧築膚簾鬱繭夢衊 鬱衊衊築顧壓鹹窪簾網 (繭願選網範簾獵膚憲衊 ) | |||||||
N/A | - | 糧蓋獵糧遞糧遞鹽選夢(構觸範鏇構醖鬱構遞餘) = 齋築糧齋鏇夢範窪膚廠 網築願遞蓋窪醖壓餘選 (淵積鏇糧膚夢範餘鹹糧 ) | - | 2010-11-16 | |||
糧蓋獵糧遞糧遞鹽選夢(構觸範鏇構醖鬱構遞餘) = 襯繭積觸鏇選範獵鏇鏇 網築願遞蓋窪醖壓餘選 (淵積鏇糧膚夢範餘鹹糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用